As electronic health records (EHRs) become standard in practice, it is important to consider their value as well as address any challenges that affect their utilization. In this segment, Peter Salgo, MD; John L. Fox, MD, MHA; Michael Kolodziej, MD; Bryan Loy, MD; and Irwin W. Tischler, DO, discuss the impact of EHR adoption on medical oncology.
Dr Tischler notes that when constructed correctly, EHR programs are extremely valuable in promoting continuity of care. However, he remarks that the programs must be interchangeable. Many different companies currently offer EHR programs, but not every program is compatible with every other. Also, some EHR programs are easy to use, and others more difficult.
The panelists also discuss the cost burden on small practices of adopting EHR programs. The adoption of an EHR program is essential to the practice of medical oncology; however, small practices are especially impacted by the high costs of these programs. In some instances, the cost of EHR programs may influence a small practice’s decision of whether to become part of a hospital-affiliated system.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More